Abstract Immunoglobulin E (IgE) plays a central role in type I hypersensitivity including allergy and asthma. Novel treatment strategy envisages development of a therapeutic vaccine designed to elicit autologous blocking antibodies against the IgE. We sought to develop an IgE-epitope antigen that induces antibodies against a receptor-contacting epitope on human IgE molecule. We designed the VLP immunogens which utilize hepatitis B virus core protein (HBcAg) as a carrier, and present arrays of the receptorcontacting epitopes of the human IgE on their surfaces. FG loop from the IgE domain Ce3 was engineered into the HBcAg. Two constructs explore a well-established approach of insertion into a main immunodominant region of the HBcAg. Third construct is different in that the carrier is produced in a form of an assembly of two polypeptide chains which upon expression remain associated in a stable VLP-forming subunit (SplitCore technology). No VLPs were isolated from E.coli expressing the IgE-epitope antigens with contiguous sequences. On the contrary, the SplitCore antigen carrying the FG loop efficiently formed the VLPs. Immunization of mice with the VLPs presenting receptor-contacting epitope of the IgE elicited antibodies recognizing the human IgE in ELISA.
Introduction
B-cell epitope-based vaccine is a concept involving artificial antigen which comprises one or more precisely defined antigenic determinants or epitopes taken out from the natural antigen and embedded into a suitable carrier [1] [2] [3] . The epitope-based vaccines have an important advantage, which is the ability to elicit immune response against a precisely defined antigenic determinant. Viruslike particles (VLPs) represent an efficient self-adjuvanting vaccine platform [4] [5] [6] . VLPs are potent immunogens capable of priming T-cell-dependent responses, and also induce T-cell-independent antibody responses. Repetitive structural arrangement of epitopes (epitope array) on the surface of the VLPs cross-links B-cell receptors (BCR), and the cross-linking triggers the T-cell-independent B-cell activation [7, 8] . Of particular importance is the fact that the presentation of epitopes in a form of highly repetitive and ordered (quasi-crystalline) array on the surface of VLPs may overcome B-cell unresponsiveness toward self-antigens [9] [10] [11] . Various types of the VLP antigens have been used to elicit autoantibodies against the autologous molecules IL-1, IL-4, IL-10, IL-17, and IL-23 and have been shown to overcome B-cell tolerance [12] [13] [14] [15] [16] .
Among proteins exerting a VLP-forming capacity, core protein of hepatitis B virus (HBV) is particularly an attractive VLP carrier because of its small size and high immunogenicity [17] . The HBcAg forms particles resembling nucleocapsids of HBV, although devoid from viral genome. These particles have spherical symmetry and are present in two forms, one form composed from 120 HBcAg dimers (triangulation number T4; diameter *34 nm) and the other composed from 90 dimers (T3; diameter *30 nm). Predominantly, alpha-helical 3D structure of the HBcAg contains an alpha-hairpin which participates in the formation of a spike, in which the tip is called the major immunodominant region (MIR) [18] . The MIR is the preferred place for insertion of B-cell epitopes because inserted sequences are exposed on the outer surface of the VLPs [19, 20] .
Immediate (type I) hypersensitivity disorders such as contact dermatitis (eczema), hay fever, intolerance of particular foods, and also including allergic bronchial asthma, are among the commonest chronic diseases in developed countries. Pathological mechanism of the type I hypersensitivity involves hyperproduction of immunoglobulin of class E (IgE) and a series of pathological reactions involving the IgE. The IgE attaches to effector cells (mast cells and basophils) through interaction with a high affinity receptor FceRI. Subsequent exposure to allergen and binding of the multivalent allergen to the specific IgE on cell membranes leads to cross-linking of the receptor molecules. Such cross-linking in turn triggers activation of the effector cells, release of mediators of vascular permeability and smooth muscle contraction. Crucial role of the IgE in the pathological mechanism of allergies and asthma makes IgE an attractive target for therapeutic intervention. Passive anti-IgE immunization via injection of a therapeutic anti-IgE monoclonal antibody (mAb) Omalizumab (Xolair) results in a clinical benefit. Alternative promising treatment approach is a therapeutic vaccination of a patient with an anti-IgE therapeutic vaccine, which is yet to be developed. Extensive efforts were made to develop antigens capable of eliciting autologous IgE-blocking antibodies of classes G and A (anti-IgE IgG and IgA) [21] [22] [23] [24] . The induced antiIgE antibodies may be targeted to a receptor-contacting epitope on the IgE molecule. Binding of the immune antiIgE with the receptor-contacting site on the IgE molecule will neutralize the main biologic function of IgE-its ability to trigger the effector cells and cause hypersensitivity reactions. However, in this approach the anti-IgE antibodies should be precisely targeted to the carefully selected epitopes on the IgE molecule. Otherwise, these blocking antibodies may cross-link the receptor-bound IgE and cause anaphylaxis.
In this paper, we describe antigens created to test a technology of presentation of the IgE receptor-contacting site on the VLPs. These HBcAg-based VLPs are designed to superficially present an FG loop of a third domain (Ce3) of the human IgE heavy chain.
Materials and Methods
Bacterial Strains, Plasmids, and Synthetic Genes The E. coli strain JM109 was used for genetic engineering, and the strain BL21(DE3) was used for expression. Gene encoding the HBcAg (subtype ayw) was produced utilizing the method of the de novo gene synthesis (described elsewhere). The HBcAg gene was used to produce three other genes encoding the HBcAg with insertions of an IgE peptide. The inserted sequence corresponds to an FG loop of the IgE domain Ce3. Hexahistidine tags (6xHis) were added to the N-ends of expression products for subsequent use of metal affinity chromatography. Cloning into expression plasmid pET22 (Novagen) was done in a way which leaves no extra aminoacid sequences attached to the expression products.
Expression of the Recombinant Proteins and Purification of VLPs
Transformed cells of the strain BL21(DE3) were inoculated into night cultures in LB medium with 100 lg/ ml ampicillin. Next day, the night cultures were transferred to 1 l of LB medium with ampicillin (100 lg/ml). Cultures were grown at 37°C, 150 rpm, until optical density at 600 nm reaches 0.6-0.8. Then, IPTG was added to a final concentration of 1 mM and incubation proceeded at room temperature (RT) for 12-16 h. Bacterial cells were collected by centrifugation (6000 rpm, 10 min, 4°C), and 10 % suspension of a pellet was prepared in a lysis buffer (20 % sucrose, 20 mM HEPES pH 7.5, 5 mM EDTA, 0.1 % Triton-X100, 1 mg/ml lysozyme, 10 lg/ml DNAse I, 100 lg/ml RNase, 0.2 mM PMSF). The suspensions were incubated at RT for 1 h. The completeness of lysis of bacterial cells was achieved by sonication using ultrasound sonicator UP200S (Hielscher). Seven pulses were made (0.9 cycle, 90 % amplitude) each for 30 s, with 1 min pauses to avoid overheating. Urea was added to a final concentration of 0.5 M, and solution was incubated on ice for 30 min. Upon clarification by centrifugation (10,000 rpm, 30 min, 4°C), the supernatants were collected for isolation of the VLPs. The VLPs were purified using a sedimentation velocity ultracentrifugation in sucrose gradients (10-60 %). To prepare a gradient, 4.5 ml portions of sucrose solutions with w/w concentrations of 60, 50, 40, 30, 20, and 10 % were layered into 38.5 ml tubes for rotor Beckman SW28. Sucrose solutions were prepared on HN buffer (20 mM HEPES pH 7.5, 150 mM NaCl). The VLP-containing samples were layered on top of gradients, and ultracentrifugation proceeded at 28,000 rpm for 4 h at 20°C. Gradients were divided into 13 fractions.
In some experiments, proportionally smaller volumes were used to perform gradient ultracentrifugation in a rotor Beckman SW41Ti. The density of solutions was determined using Abbe refractometer. The fractions were examined in SDS-PAGE and those fractions which contained the recombinant protein were combined. Sucrose was removed from the VLP-containing probe by overnight dialysis against 2 l of HN buffer. If higher purity was desired, the VLPs were subjected to the second round of ultracentrifugation in the same conditions.
Native Agarose Gel Electrophoresis
Analysis of the VLP production and integrity was done using a native agarose gel electrophoresis (NAGE). In the NAGE, VLPs migrate as distinct bands, as is opposed to various contaminants which produce smears. Gels of 1 % agarose were prepared on 19 TAE (40 mM Tris acetate, pH 8.0, 5 mM sodium acetate, 1 mM EDTA) and run in 19 TAE at 1 V/cm field strength, for 40 min. For quick visual assessment of the presence of VLPs in the samples, a dye brilliant cresyl blue (BCB) (Sigma Cat# B5388) was added to a final concentration 0.001 % to a molten agarose before casting. During electrophoresis in the BCB-containing gels, the dye binds to proteins and VLP bands become visible. If more sensitivity was desired, gels were also stained post-electrophoresis with coomassie brilliant blue R250.
Removal of Endotoxin
Samples were concentrated to protein concentration 1-2 mg/ml using Vivaspin 6 centrifugal concentrator with a molecular weight cut-off 100 kDa (Vivaproducts). Bacterial endotoxin (LPS) was removed from samples using a temperature-induced phase separation with Triton X-114 [25] . The Triton X-114 was added to a final concentration of 1 %, and the mixture was vigorously shacked on Vortex for 1 min. The tube was placed on ice for 5 min to allow the sample to become fully transparent. Then, the tube was incubated in a water bath at 56°C for 5 min to allow phase separation. Opaque sample was centrifuged for 7 s at 13,200 rpm. Aqueous phase containing the VLPs was collected from above the droplet of detergent and transferred into a new tube. This procedure of the extraction of LPS was repeated two more times. Residual Triton X-114 was removed from the VLP solution by dialysis against 1 L of phosphate-buffered saline (PBS). Limulus amebocyte lysate test Endosafe-PTS (Charles River) was used to check for the residual endotoxin which was always less than 50 EU/ml.
Electron Microscopy and Dynamic Light Scattering
Drops of the VLP solutions were placed on a sheet of parafilm. Carbon-formvar-coated copper grids (Ted Pella) were allowed to float on the droplets with coated side down, for 5 min. The grids were dried by touching the filter paper with their edges. Then, grids were placed onto drops of a 2 % solution of phosphotungstic acid pH 7.0 and were allowed to float for 5 min. Excess of the contrasting agent was removed with filter paper, and the grids were air-dried for 3 min. The grids were examined using a transmission electron microscope (LIBRA 120, Carl Zeiss) at magnifications 30,000-100,0009. Sizes of the VLPs were also measured by dynamic light scattering (DLS) using DLS scanner Nanotrac Wave (Microtrack).
Immunization of Mice
BALB/c mice were used for immunizations. Baseline (preimmunization) sera were collected and pooled. The immunization scheme included three subcutaneous (sc) injections: 25 lg of the VLP antigen, in PBS (0.2 ml) mixed with a complete Freund's adjuvant (1:1) for the first injection, and 25 lg of the VLP antigen in PBS without adjuvants for the other two shots. Immunization shots were given at days 0, 21, and 42. Mice were bled from tail veins at day 56 after the first immunization. Control group was immunized with the empty carrier (HBcAg). Experimental group was immunized with the SplitCore IgE antigen. Sera from individual mice were pooled within the control and experimental groups. Experiments were approved by the Animal Ethics Committee (AEC) in the National Center for Biotechnology (Astana).
Western Blotting
Proteins were resolved in 15 % denaturing polyacrylamide gels (SDS-PAGE). Upon the SDS-PAGE, proteins were electro-transferred to a nitrocellulose membrane (Amersham). The membrane was blocked with PBST?BSA (phosphate-buffered saline containing 0.05 % Tween 20 and 1 % bovine serum albumin) at 4°C overnight. Next day, the membrane was incubated for 1 h with anti-HBcAg monoclonal antibody 10C6 (Abcam, Cat# ab20749), diluted 1:1000 in PBST?BSA. Upon three 30-min washes in PBST, the membrane was incubated for 1 h with antimouse IgG conjugate with horseradish peroxidase (Sigma, Cat# A9044) diluted 1:5000 in PBST?BSA. Upon three washes in PBST and three washes in water, the membrane was incubated for 10 min in a solution of 4-chloro-1-naphthol (0.06 %) and hydrogen peroxide (0.03 %) in PBS.
Enzyme-Linked Immunosorbent Assay (ELISA)
Purified human IgE (Abcam, Cat# ab65866) was used as a capture antigen in ELISA to detect anti-IgE antibodies in mouse sera. The IgE solution (5 lg/ml) in a 50 mM sodium carbonate buffer pH 9.6 was dispensed into wells of a 96-well plate (Costar), and the plate was incubated overnight at 4°C. The PBST was used as a washing buffer, and a PBST?BSA was used as a blocking buffer and a diluent for serum. After blocking for 1 h at 37°C, serial dilutions of pooled mouse sera (from 1:50 to 1:109,350) were dispensed into wells. The plate was incubated for 1 h at 37°C. Upon three washes with the PBST, a horseradish peroxidase-conjugated anti-mouse IgG antibody (Sigma, Cat# A9044) diluted 1:10,000 in the PBST was applied. Following 1 h of incubation at 37°C, the plate was washed 3 times with the PBST and then 3 times with water. The liquid substrate system for ELISA (Sigma, Cat# T0440) was added. Color reaction was stopped by the addition of 2 M sulfuric acid. Absorbance values were read at 450 nm using an ELISA plate reader. Titer was defined as the highest dilution of serum from mice immunized with the IgE-epitope antigen that resulted in an absorbance in ELISA two times that of the control serum.
Results

Engineering of the IgE-Epitope Antigens
Sequences of the recombinant expression products described in this paper are presented in Fig. 1 . We truncated sequences of the recombinant antigens at Val 149 (all positions are referenced according to sequence of the native HBcAg) to remove C-terminal protamin-like domain which is not required for the VLP assembly. To produce the IgE epitope-carrying VLPs, sequence GETYQSRVTHPHLPRALMRSTTK derived from the human IgE was cloned into the HBcAg MIR site (Fig. 1) . Sequence of the IgE epitope is flanked with flexible glycine-rich linkers, G 4 E 2 SG 4 T and TG 4 SE 2 G 4 which are intended to minimize interference between tertiary structure of the HBcAg and that of the heterologous insert.
Three different variants of insertion were tried. The first variant, namely the HBcAg-IgE is the HBcAg with insertion of the IgE peptide into the MIR site. No attempt was made to achieve cyclization of the insert in the HBcAgIgE. Considering known loop conformation of the selected IgE fragment [24, 26] , the cyclization of the inserted sequence seemed to be a desired property. Thus, in the second variant, namely the HBcAg-IgE(Cys), the cysteine residues were engineered to immediately flank the IgE peptide. Formation of disulfide bond between the flanking Cys residues is thought to provide an additional conformational constraint (cyclization) to the IgE epitope. The third variant, namely the HBcAg-IgE(SC) was developed utilizing a SplitCore technology described in [27] . Unlike traditional carriers, which exist as single polypeptide chains, the SplitCore is an assembly composed from two different polypeptide chains corresponding to N-and C-terminal parts of the HBcAg and designated accordingly as HBcAg-IgE(SC)N and HBcAg-IgE(SC)C. Translation of the two polypeptide chains occurs from a single bicistronic mRNA, from separate ORFs (Fig. 2) . To produce a SplitCore expression construct, a termination codon, a ribosome-binding Shine-Dalgarno sequence, and a second copy of the initiation codon ATG were engineered into the HBcAg gene. Upon translation, the HBcAg-IgE(SC)N and HBcAg-IgE(SC)C remain associated in a stable complex, which is structurally similar to one HBcAg molecule and is capable of formation of the VLPs [27] . To embed the IgE epitope into the recombinant antigen, the IgE peptide sequence was added to the C-terminus of the HBcAgIgE(SC)N part. One linker was preserved for compatibility between the constructs.
Purification of VLPs
The VLPs were purified using sedimentation through sucrose gradients. Fractions from gradients were examined in NAGE to analyze for the presence of the VLPs. Distinct bands were observed for the HBcAg (Fig. 3a, lanes 8-13) .
As inferred from results of the NAGE, the HBcAg is distributed along gradient in a wide range of buoyant densities (1.16-1.28 g/ml). Fractions of sucrose gradients for the proteins HBcAg-IgE and HBcAg-IgE(Cys) in the NAGE produced a different pattern (Fig. 3b, c) . For the latter constructs, distinct bands were observed for only one or two gradient fractions. These fractions were of lower buoyant density compared to that of the HBcAg, i.e., for the HBcAg-IgE-1.09 g/ml (Fig. 3b, lane 5) , and for the HBcAg-IgE(Cys) 1.09-1.12 g/ml (Fig. 3c, lanes 5-6) . For the SplitCore construct HBcAg-IgE(SC), gradient fractions #8 and #9 contained material giving distinct bands in the NAGE (Fig. 3d, lanes 8-9) . Density of sucrose solution in the fractions #8 and #9 was 1.16-1.21 g/ml. The recombinant HBcAg produced in E. coli stays in a soluble (cytoplasmic) fraction. On the contrary, at least 8 times lower production into the soluble fraction was observed for the IgE-epitope antigens (data not shown). Remaining amounts of the IgE-epitope antigens were found in pellets (data not shown). To avoid refolding of the expression products and in vitro reassembly of the VLPs, we purified antigens from the clarified supernatants.
The concentrated samples were analyzed in SDS-PAGE (Fig. 4) . HBcAg produced band in good agreement with the expected Mw (*19 kDa) (Fig. 4, lane 1) . For the recombinant proteins, HBcAg-IgE and HBcAg-IgE(Cys), doublets with Mw near expected range were observed (Fig. 4, lanes 2, 3) . We speculate that the probable reason for the appearance of doublets is that they contain mixtures of proteins with complete N-end and with truncated N-end. The N-termini of the expression products contain two methionine codons spaced apart by ten residues (MGHHHHHHSGGM). It is probable that translation of the recombinant proteins is initiated from both ATG codons, and thus two translation products are formed within the expressing cell. One protein is full-length and the second translation product is truncated by 11 aa residues. Although no regular VLPs were detected for HBcAgIgE and HBcAg-IgE(Cys), the two samples contain aggregates with DLS-determined diameters *10 nm (Fig. 5) . It is probable that the aggregates contain mixtures of the full-length and truncated products which give rise to the doublets. The SplitCore IgE antigen produced three bands (Fig. 4, lane 4 ) from which two bands correspond well to the HBcAg-IgE(SC)N (Mw*14 kDa) and HBcAgIgE(SC)C (Mw*8 kDa). The nature of the third band (*18 kDa) is obscure. It may represent a conformational form of the N-terminal part of the HBcAg-IgE(SC) since this band does not react with mAb targeting the C-end of HBcAg (Fig. 7) . The HBcAg-IgE(SC)N has two Cys residues flanking the FG loop sequence. It is possible that these Cys residues produce stable disulfide bonding which survives treatment during the preparation of samples for the SDS-PAGE.
Sizing of the HBcAg and the SplitCore VLPs
Measurement of sizes of particles using DLS confirmed the presence of particles with a mean diameter *34 nm in the sample of HBcAg (Fig. 5a) . Particles with a similar diameter were found in a sample of the SplitCore antigen (Fig. 5d) . Diameter of 30-34 nm is characteristic to the HBcAg VLPs. On the contrary, samples of the HBcAg-IgE (Fig. 5b) and HBcAg-IgE(Cys) (Fig. 5c ) contained considerably smaller particles (mean diameter 10-13 nm) which probably represent non-VLP aggregates. Electron microscopy revealed abundant VLPs in the samples of (Fig. 6a) and SplitCore IgE antigen (Fig. 6b) . Diameters of particles observed on microphotographs are consistent with the DLS data. In a majority of experiments, examination of the IgE antigens with contiguous sequences did not result in the revealing of particles with regular morphology (although we occasionally observed few amounts of regular spherical particles in these preparations). Besides inability of the HBcAg-IgE and HBcAgIgE(Cys) to form VLPs, these results may indicate that the relative VLPs are unstable and do not survive isolation.
Confirmation of the Immunologic Specificity of the Recombinant Proteins
The recombinant proteins HBcAg and HBcAg-IgE(SC) reacted with the anti-HBcAg mAb 10C6 (Fig. 7) . The mAb 10C6 recognizes a linear epitope a.a. 138-145 of the HBcAg (subtype ayw) and this mAb reacts with denatured proteins. Molecular masses of the major bands observed in the blot correspond to the calculated Mw for monomeric polypeptide chains. The calculated molecular masses are 19 kDa for the HBcAg, and 8 kDa for the HBcAgIgE(SC)C, the latter is the C-terminal part of the SplitCore antigen.
ELISA Detects Induced Anti-(Human) IgE Antibodies
Eight-week-old female BALB/c mice were purchased from local breeding center. Mice were divided into two groups, 5 mice/group. Blood was taken from tail veins of all animals to obtain the baseline sera (*0.1-0.25 ml from mouse) which were pooled. Subcutaneous (s.c.) immunizations were performed by injecting antigens (0.4 ml / mouse) into the scruff of the neck. Antigens for injections were prepared by replacing buffer with PBS using centrifugal filter device. For the first shot, antigen solution (diluted in PBS to 125 lg/ml) was mixed 1:1 with the CFA and briefly sonicated. The emulsion was promptly injected giving the first immunization (day 0). For the 2nd and 3rd shots, doses of antigen (25 lg in 0.4 ml) were administered at days 21 and 42. Group 1 received the SplitCore IgE antigen; group 2 received the HBcAg in the same dosage. Blood was collected from tail veins on day 56, and the sera were pooled within each group. Direct ELISA was used to determine antigenicity of the IgE epitope presented on the surface of VLPs. Microtitration plates were coated with the human IgE and probed with sera from mice immunized with the SplitCore IgE antigen and empty carrier (control). The human immunoglobulin IgE was recognized by antibodies elicited by immunization of mice with the antigen HBcAg-IgE(SC) (Fig. 8) . Titer of anti-(human) IgE-epitope antibodies which is dilution of the experimental serum producing OD value twice that of the control serum reached 1:36,450 (Fig. 8) .
Discussion
In this study, we aimed to explore the VLP-forming property of the HBcAg to produce antigens capable of eliciting antibodies against the receptor-contacting loop of the human IgE. Search for the receptor-contacting IgE epitopes may be based on a crystal structure of the IgE/ receptor complex [26, 28] . Binding of the IgE-Fc to the FceRI is asymmetric [29] . Two heavy chains of one IgE molecule have different amino acid sequences involved in contacts with the receptor [26] . Subdomains reported to contact the receptor FceRI include a linker connecting the IgE domains Ce2 and Ce3 (Ce2-Ce3 linker, residues 334-336), and the Ce3 loops BC (residues 362-365), DE (393-396), and FG (424-427) [28, 30, 31] . The FceRI molecule has two cavities, namely P426 and Y131 pockets [26] . Two subdomains of the one heavy chain, namely the FG loop apical residues (H 424 LPR 427 ) and the Ce2-Ce3 linker, bind to P426 pocket, whereas four subdomains of the other heavy chain, namely the FG loop, the Ce2-Ce3 linker, BC and DE loops bind to the Y131 receptor pocket. Involvement of the FG loop in the receptor recognition is underscored by the fact that the binding site for the blocking antibody Omalizumab maps to the FG loop [32, 33] . Another demonstration of utility of the FG loop for the development of anti-IgE vaccines came from mapping of the IgE epitopes using synthetic peptides [24, 34] . In one study [24] , peptide GETYQSRVTHPHLPRALMRSTTK is described, which was selected from 35 candidate peptides mapping to the Ce2, Ce3, and Ce4 domains. In an antigen used for experimental immunizations [24] , the FG loop was mimicked by cyclic peptide which was produced by addition of flanking cysteines to the mentioned aminoacid sequence. Immunogenicity of the synthetic peptide was increased by conjugation to a promiscuous T-helper epitope [24] . Immunization with the resulting antigen induced the anti-IgE polyclonal antibodies which blocked the IgE binding to the FceRI, reduced histamine release by sensitized basophils, inhibited passive cutaneous anaphylaxis, and importantly, did not cause degranulation [24] .
Approaches to immunopotentiate the IgE peptides include chemical conjugation to the KLH [24] , Q beta phage particles (as described in a series of patents including US20140017239 ''IGE CH3 Peptide Vaccine'') or the hepatitis B surface antigen (HBsAg) [23] . To immunopotentiate the receptor-contacting site of the human IgE, we engineered the FG loop onto surface of the VLPs formed from the HBcAg. Surface location of the epitope was achieved via insertion into the spike domain (MIR) of the HBcAg. Sequence of the insert GETYQSRVTHPHL-PRALMRSTTK differs from the homologous region of the human IgE by one mutation (Cys to Ser). This mutation was intentionally introduced to prevent formation of disulfide pairings involving the insert-internal Cys residue. Random disulfide pairings may occur in recombinant proteins and affect protein folding and the formation of the VLPs.
We designed three variants of recombinant proteins comprising the HBcAg as a carrier and the FG loop as an insert. The first variant (HBcAg-IgE) has contiguous aminoacid sequence with the insert flanked with long glycinerich linkers. It is generally assumed that the flexible linkers facilitate correct folding of the fusion proteins. In case of complex inserts, sufficiently long flexible linkers were needed to preserve the ability of the carrier to form VLPs [35] . The second variant (HBcAg-IgE/Cys) has contiguous sequence in which the insert is additionally flanked with adjacent Cys residues. The flanking Cys residues were introduced with the intention to cyclize the insert as was done to the FG loop sequence in [24] . However, both variants of the IgE-epitope antigens with contiguous sequences did not Fig. 8 Reaction with purified human IgE in ELISA (0.5 lg / well). Pooled mouse serum was diluted as indicated and tested for reactivity with the human IgE: (1) serum from mice immunized with the SplitCore IgE antigen; (2) serum from mice immunized with the HBcAg (control); (3) baseline (pre-immunization) serum produce VLPs, probably because of structural incompatibility between the carrier and the inserts. The third variant is an example of the utilization of a novel and highly flexible approach for incorporation of foreign sequences into the hepadnavirus core which renders the resulting proteins capable of formation of VLPs [27] . It relies on the expression of two polypeptides corresponding to the N-and C-terminal parts of the HBcAg from separate ORFs. The two ORFs in one bicistronic RNA are separated by an engineered internal ribosome binding site (iRBS) [27] . When applied as a carrier for presentation of the FG loop epitope, the SplitCore technology enabled the production of a significant portion of the antigen into a soluble (cytoplasmic) fraction. Our data are in concordance with the results published in [27] in which the SplitCore solves problems of structural incompatibility between the hepadnavirus core and complex inserts. Our results demonstrate utility of the SplitCore technology for eliciting IgE-reactive antibodies. The effects of these antibodies on blocking allergic reactions will be assessed in future studies.
